Merck KGaA: EPS $0.24 vs $0.50 expected; revenue $6.24B vs $6.15B
Key Facts
Q3 FY2026 results
| Metric | Actual | Estimate | Surprise | Year ago |
|---|---|---|---|---|
| EPS (USD) | 0.24 | 0.50 | −52.0% | 0.81 |
| Revenue (USD bn) | 6.24 | 6.15 | +1.5% | 6.17 |
Recent reports: actual vs estimate
| Reported | Period | EPS (USD) | Estimate | Surprise | Revenue (USD bn) | Estimate | Surprise |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Q3 FY2026 | 0.24 | 0.50 | −52.0% | 6.24 | 6.15 | +1.5% |
| Aug 6, 2026 | Q2 FY2026 | 0.26 | 0.47 | −44.7% | 6.27 | 6.08 | +3.1% |
| May 13, 2026 | Q1 FY2026 | 0.59 | 0.45 | +31.1% | 6.01 | 5.93 | +1.3% |
| Mar 5, 2026 | Q4 FY2025 | 0.28 | 0.47 | −40.4% | 6.08 | 6.20 | −2.0% |
| Nov 13, 2025 | Q3 FY2025 | 0.81 | 0.54 | +50.0% | 6.17 | 6.08 | +1.4% |
| Aug 7, 2025 | Q2 FY2025 | 0.57 | 0.51 | +11.8% | 6.19 | — | — |
| May 15, 2025 | Q1 FY2025 | 0.59 | 0.50 | +18.0% | 5.79 | 5.33 | +8.5% |
| Mar 6, 2025 | Q4 FY2024 | 0.54 | 0.47 | +14.9% | 5.61 | 5.34 | +5.1% |
Source: Figures from the EL7 database. Estimates are the analyst consensus carried by our data vendor (FMP), not official figures. Figures are in USD as carried for this US-traded line; the company reports in another currency.
Merck KGaA results: EPS $0.24 vs $0.50 expected; revenue $6.24B vs $6.15B. The results cover the company's Q3 FY2026. EPS came in below analysts' estimate by 52.0%; revenue above the estimate by 1.5%. Figures are in USD as carried for this US-traded line; the company reports in EUR.
Revenue was up 1.3% from $6.17 billion a year earlier (Q3 FY2025). EPS was down 70.4% from $0.81 a year earlier. On its record, EPS topped analysts' estimates in 5 of 7 earlier comparable reports.
What the results mean
Merck combines Life Science, Healthcare and Electronics, so interpreting its results requires attention to demand across distinct businesses. Laboratory tools and drug manufacturing technologies serve researchers and biotechnology companies, while electronic materials serve semiconductor and display manufacturers.
In Life Science, the business extends from reagents and research equipment to drug manufacturing process development, testing and analytical services. Healthcare spans prescription medicines and biopharmaceuticals across varied therapeutic areas, alongside injection devices and disease monitoring software. This breadth makes the mix of products and services important to understanding business performance.
What to watch on the earnings call: Demand for laboratory tools and drug manufacturing technologies, the mix of medicines and therapeutic areas in Healthcare, semiconductor and display manufacturers’ needs for electronic materials, and management’s discussion of how products and services contribute to each business.
For the full analysis of Merck KGaA stock — valuation, scores and financial statements — see the stock page linked with this story.